Literature DB >> 22057510

Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: is rechallenging safe?

Harsha Prasada Lashkari1, Donna Lancaster, Ayad Atra, Michael P Champion, Mary M Taj.   

Abstract

Severe hyperlipidaemia with asparaginase therapy is rare. We report six cases, four of which developed significant problems with severe hyperlipidaemia during induction therapy for ALL and lymphoblastic lymphoma. The median triglyceride level was 22.3 mmol/L and the median cholesterol level was 12.3 mmol/L. None of the patients showed signs or symptoms of pancreatitis. Three children were re-exposed with Peg asparaginase, and one with Erwinia asparaginase, without recurrence of hyperlipidaemia or other symptoms. These cases highlight the dilemma in managing such rare cases of symptomatic hypertriglyceridaemia secondary to asparaginase and steroid therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22057510     DOI: 10.1007/s12185-011-0966-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  17 in total

Review 1.  The use of statins in pediatrics: knowledge base, limitations, and future directions.

Authors:  Brook Belay; Peter F Belamarich; Catherine Tom-Revzon
Journal:  Pediatrics       Date:  2007-02       Impact factor: 7.124

Review 2.  Hyperlipidemic pancreatitis.

Authors:  P P Toskes
Journal:  Gastroenterol Clin North Am       Date:  1990-12       Impact factor: 3.806

Review 3.  Issues in hyperlipidemic pancreatitis.

Authors:  Dhiraj Yadav; C S Pitchumoni
Journal:  J Clin Gastroenterol       Date:  2003-01       Impact factor: 3.062

4.  Pancreatitis may occur with a normal amylase concentration in hypertriglyceridaemia.

Authors:  P Sharma; S Lim; D James; R T Orchard; M Horne; C A Seymour
Journal:  BMJ       Date:  1996-11-16

5.  Predicting asparaginase-associated pancreatitis.

Authors:  Holly M Knoderer; Jason Robarge; David A Flockhart
Journal:  Pediatr Blood Cancer       Date:  2007-10-15       Impact factor: 3.167

6.  Toxicity of E. coli L-asparaginase in man.

Authors:  H F Oettgen; P A Stephenson; M K Schwartz; R D Leeper; L Tallai; C C Tan; B D Clarkson; R B Golbey; I H Krakoff; D A Karnofsky; M L Murphy; J H Burchenal
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

7.  Transient hyperlipidemia during treatment of ALL with L-asparaginase is related to decreased lipoprotein lipase activity.

Authors:  N Hoogerbrugge; H Jansen; P M Hoogerbrugge
Journal:  Leukemia       Date:  1997-08       Impact factor: 11.528

Review 8.  Severe hypertriglyceridemia and pancreatitis: presentation and management.

Authors:  Nils Ewald; Philip D Hardt; Hans-Ulrich Kloer
Journal:  Curr Opin Lipidol       Date:  2009-12       Impact factor: 4.776

9.  Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.

Authors:  Hofit Cohen; Bella Bielorai; Dror Harats; Amos Toren; Orit Pinhas-Hamiel
Journal:  Pediatr Blood Cancer       Date:  2010-05       Impact factor: 3.167

10.  Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.

Authors:  Amrana Qureshi; Chris Mitchell; Sue Richards; Ajay Vora; Nick Goulden
Journal:  Br J Haematol       Date:  2010-03-10       Impact factor: 6.998

View more
  2 in total

1.  Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia.

Authors:  Deepa Bhojwani; Rashid Darbandi; Deqing Pei; Laura B Ramsey; Wassim Chemaitilly; John T Sandlund; Cheng Cheng; Ching-Hon Pui; Mary V Relling; Sima Jeha; Monika L Metzger
Journal:  Eur J Cancer       Date:  2014-07-30       Impact factor: 9.162

2.  Case Report: The Use of Intravenous SMOFlipid Infusion to Treat Severe Asparaginase-Induced Hypertriglyceridemia in Two Pediatric Acute Lymphoblastic Leukemia Patients.

Authors:  Sie Chong Doris Lau; C-Khai Loh; Hamidah Alias
Journal:  Front Pediatr       Date:  2021-04-22       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.